Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Income taxes by Year
Income taxes — Gross deferred tax assets (before valuation allowance) ($M) ($M)
Moderna Income taxes: $4,014M in FY2025, up 19.4% from a year earlier. That is the highest of the 8 years on record here.
Latest, FY2025
4,014
Period ended Dec 31, 2025
Change on a year earlier
+19.4%
3,361 in FY2024
History
8 years
Since FY2018
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-K Note 15 (Income Taxes).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Income taxes — Gross deferred tax assets (before valuation allowance) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4,014 | +19.4% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 3,361 | +25.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 2,678 | +96.0% | Form 10-K (filed 2025-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 1,366 | +102.4% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 675 | -22.8% | Form 10-K (filed 2023-02-24) ↗ |
| FY2020 | Dec 31, 2020 | 874 | +72.3% | Form 10-K (filed 2022-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 507 | +56.8% | Form 10-K (filed 2021-02-26) ↗ |
| FY2018 | Dec 31, 2018 | 324 | – | Form 10-K (filed 2020-02-27) ↗ |
Breakdown
What makes up income taxes
- Deferred tax asset — Capitalized R&D expenses ($M)1,693 · FY2025
- Deferred tax asset — Net operating loss (NOL) carryforwards ($M)1,156 · FY2025
- Deferred tax asset — R&D and tax credit carryforwards ($M)308 · FY2025
- Deferred tax asset — Stock-based compensation ($M)129 · FY2025
- Deferred tax asset — Inventory reserves ($M)152 · FY2025
- Deferred tax asset — Lease liabilities ($M)134 · FY2025
- Deferred tax asset — Sales returns and rebates reserves ($M)116 · FY2025
- Deferred tax asset — Chargebacks and discounts reserves ($M)26 · FY2025
- Deferred tax asset valuation allowance ($M)3,738 · FY2025
- Deferred tax assets, net of valuation allowance ($M)276 · FY2025
- Unrecognized tax benefits (UTB) ending balance ($M)241 · FY2025
Cite this data
StockData. (2026). Moderna Income taxes ($M), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/dta-gross
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.